Alterity Therapeutics Ltd logo

Alterity Therapeutics Ltd

ASX:ATH (Australia)  
A$ 0.01 (0%) Dec 24
N/A
P/B:
2.00
Market Cap:
A$ 31.47M ($ 19.65M)
Enterprise V:
A$ 18.99M ($ 11.86M)
Volume:
2.38M
Avg Vol (2M):
10.08M
Trade In:
Volume:
2.38M
Avg Vol (2M):
10.08M

Business Description

Description
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 79.49
Equity-to-Asset 0.72
Debt-to-Equity 0.01
Debt-to-EBITDA N/A
N/A
N/A
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 49.16
9-Day RSI 54.16
14-Day RSI 56.43
6-1 Month Momentum % -33.33
12-1 Month Momentum % -50

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.54
Quick Ratio 3.54
Cash Ratio 2.35

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -36
Shareholder Yield % -32.07

Profitability Rank

Name Current Vs Industry Vs History

GF Value Rank

Name Current Vs Industry Vs History
PE Ratio N/A
N/A
N/A
PE Ratio without NRI N/A
N/A
N/A
PB Ratio 2
EV-to-EBIT -0.98
EV-to-Forward-EBIT -0.7
EV-to-EBITDA -0.99
EV-to-FCF -1.16
Earnings Yield (Greenblatt) % -102.04
FCF Yield % -52.17

Financials

ASX:ATH's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Alterity Therapeutics Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) 0
Beta 1.47
Volatility % 121.77
14-Day RSI 56.43
14-Day ATR (A$) 0.00094
20-Day SMA (A$) 0.005425
12-1 Month Momentum % -50
52-Week Range (A$) 0.002 - 0.008
Shares Outstanding (Mil) 5,245.66

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Alterity Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Alterity Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price(A$)
No Event Data

Alterity Therapeutics Ltd Frequently Asked Questions

What is Alterity Therapeutics Ltd(ASX:ATH)'s stock price today?
The current price of ASX:ATH is A$0.01. The 52 week high of ASX:ATH is A$0.01 and 52 week low is A$0.00.
When is next earnings date of Alterity Therapeutics Ltd(ASX:ATH)?
The next earnings date of Alterity Therapeutics Ltd(ASX:ATH) is .
Does Alterity Therapeutics Ltd(ASX:ATH) pay dividends? If so, how much?
Alterity Therapeutics Ltd(ASX:ATH) does not pay dividend.

Press Release

Subject Date
No Press Release